Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2015;15(11):1315-26. doi: 10.1586/14737140.2015.1090879. Epub 2015 Nov 2.

Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.

Author information

1
a 1 Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
2
d 4 Women's College Research Institute, Women's College Hospital, Toronto, Canada.

Abstract

Multigene panel tests are being increasingly used for the genetic assessment of women with an apparent predisposition to breast cancer. Here, we review all studies reporting results from individuals who have undergone multigene panel testing for hereditary breast cancer. Across all gene panel studies, the prevalence of pathogenic mutations was highest in BRCA1 (5.3%) and BRCA2 (3.6%) and was lowest in PTEN (0.1%), CDH1 (0.1%) and STK11 (0.01%). After BRCA1/2, the prevalence of pathogenic mutations was highest in CHEK2 (1.3%), PALB2 (0.9%) and ATM (0.8%). The prevalence of variants of unknown significance was highest in ATM (9.6%). Based on the prevalence and penetrance of pathogenic mutations and the prevalence of variants of unknown significance, it is our interpretation that BRCA1, BRCA2, PALB2 and CHEK2 are the best candidates for inclusion in a clinical multigene breast cancer panel.

KEYWORDS:

breast cancer; gene panel; genetic testing; next-generation sequencing; precision medicine

PMID:
26523341
DOI:
10.1586/14737140.2015.1090879
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center